Internal Medicine, Hematology & Oncology · Anniston, AL
NPI
1689629602
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
171 Town Center Dr,, Suite 6
Anniston, AL, 36205
Phone (256) 847-3369
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.5M
129,881 services
Medicare patients, 2024
397
Average age 74
Drug cost, 2024
$14.2M
4,197 prescriptions
Company payments, 2025
$4,243
From 39 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Aasim S Sehbai was code Q0138 (injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)), 14,280 times for 18 patients. In total Aasim S Sehbai billed 129,881 services in 121 codes, and Medicare paid $1.5M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-11-20.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 14,280 | 18 | $0.09 | $1,306 |
| J1453 Injection, fosaprepitant, 1 mg | Office | 10,950 | 11 | $0.04 | $386 |
| J0897 Injection, denosumab, 1 mg | Office | 6,540 | 35 | $14.00 | $92K |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 3,160 | 33 | $0.07 | $228 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,158 | 37 | $0.09 | $190 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 1,200 | 12 | $16.06 | $19K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 910 | 13 | $0.18 | $165 |
| 96375 Injection Administration | Office | 763 | 73 | $11.16 | $8,515 |
| 96372 Injection Administration | Office | 590 | 118 | $10.60 | $6,252 |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 562 | 48 | $36.53 | $21K |
| 96367 Intravenous Infusion, Hydration | Office | 479 | 44 | $20.89 | $10K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 444 | 93 | $47.83 | $21K |
| 99214 Office E&M - Established | Office | 388 | 249 | $92.29 | $36K |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 381 | 72 | $0.64 | $244 |
| 96413 Chemotherapy Administration | Office | 316 | 42 | $92.44 | $29K |
By year: 2022 $1.4M for 134,071 services; 2023 $1.6M for 156,340 services; 2024 $1.5M for 129,881 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 45 | 24 | $7.61 | $342 |
Medicare prescription drug claims, 2024
In 2024, the drug Aasim S Sehbai prescribed most often to Medicare patients was Hydrocodone-Acetaminophen (Hydrocodone/Acetaminophen), with 201 prescriptions and refills. In total Aasim S Sehbai wrote 4,197 Medicare prescriptions that cost $14.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 201 | 201 | 46 | $5,033 |
| Palonosetron Hcl Generic | 184 | 191 | 30 | $14K |
| Fosaprepitant Dimeglumine Generic | 165 | 166 | 30 | $22K |
| Procrit Epoetin Alfa | 138 | 140 | 37 | $272K |
| Neulasta Onpro Pegfilgrastim | 128 | 128 | 28 | $879K |
| Gabapentin Generic | 91 | 91 | 23 | $1,056 |
| Alprazolam Generic | 85 | 85 | 19 | $174 |
| Fentanyl Generic | 83 | 83 | 18 | $7,514 |
| Oxycodone Hcl Generic | 81 | 81 | 15 | $2,114 |
| Anastrozole Generic | 75 | 190 | 30 | $1,420 |
| Xgeva Denosumab | 75 | 82 | 16 | $238K |
| Octagam Immun Globg(Igg)/Malt/Iga Ov50 | 68 | 68 | Under 11 | $394K |
| Leucovorin Calcium Generic | 67 | 68 | 13 | $6,860 |
| Promacta Eltrombopag Olamine | 64 | 64 | Under 11 | $850K |
| Somatuline Depot Lanreotide Acetate | 63 | 63 | Under 11 | $575K |
Brand drugs: - claims; generic drugs: 2,538 claims; opioid claims: 546.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Aasim S Sehbai $4,243 ($4,243 in general payments such as food, travel and fees) from 39 companies. The largest payer was Novartis Pharmaceuticals Corporation with $1,701.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 37 | $1,701 |
| Janssen Biotech, Inc. JNJ | 17 | $397 |
| AstraZeneca Pharmaceuticals LP AZN | 13 | $335 |
| Pfizer Inc. PFE | 13 | $164 |
| BeOne Medicines USA, Inc. ONC | 7 | $122 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 4 | $103 |
| Merck Sharp & Dohme LLC MRK | 5 | $97.2 |
| Abbvie Inc. ABBV | 5 | $97.15 |
| Genzyme Corporation SNY | 3 | $93.7 |
| Stemline Therapeutics Inc. | 4 | $89.64 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.